Cisplatin cycles treatment sustains cardiovascular and renal damage involving TLR4 and NLRP3 pathways

Cisplatin is clinically proven to combat different cancers, including sarcomas, soft tissue cancers, bones, muscles, and blood. However, renal and cardiovascular toxicities are important limitations in cisplatin therapeutical use. Immunoinflammation could be key factor in cisplatin‐induced toxicity....

Descripción completa

Detalles Bibliográficos
Autores principales: González, Antonio, García‐Gómez‐Heras, Soledad, Franco‐Rodríguez, Raquel, López‐Miranda, Visitación, Herradón, Esperanza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331131/
https://www.ncbi.nlm.nih.gov/pubmed/37424158
http://dx.doi.org/10.1002/prp2.1108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331131/
https://www.ncbi.nlm.nih.gov/pubmed/37424158
http://dx.doi.org/10.1002/prp2.1108

Ejemplares similares